Stay updated with breaking news from Christopher Peetz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research note issued on Tuesday, January 9th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of $3.37 for the year, […]
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report)‘s stock had its “market outperform” rating reiterated by research analysts at JMP Securities in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $64.00 price objective on the stock. JMP Securities’ price objective would indicate a potential upside of 142.15% from […]
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CEO Christopher Peetz sold 5,209 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $28.03, for a total value of $146,008.27. Following the completion of the sale, the chief executive officer now directly […]
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript November 5, 2023 Operator: Good afternoon. I would like to welcome you all to the Mirum Pharmaceuticals Conference Call. My name is Brika and I’ll be the event specialist running today’s call with you. [Operator Instructions]. I would now like to pass the call over to […]
HC Wainwright reaffirmed their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) in a report released on Friday morning, Benzinga reports. They currently have a $63.00 price objective on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q2 2024 earnings at $0.23 EPS, Q3 2024 earnings at $0.38 EPS, Q4 […]